Navidea Biopharma (NAVB) Reports Q4 Loss of $0.03
Tweet
Share
E-mailGet Alerts NAVB Hot Sheet
Join SI Premium – FREE
Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.03), versus ($0.02) reported last year. Revenue for the quarter came in at $395 thousand, versus $1 million reported last year.
For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
